The toronto observational study of natalizumab in multiple sclerosis

Canadian Journal of Neurological Sciences

Volumn 38, Issue 3, 2011, Pages 422-428

  Krysko, Kristen ^a   O'Connor, Paul ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; ROQUINIMEX; STEROID; TERIFLUNOMIDE;

ADULT; ANAPHYLAXIS; ARTICLE; BREAST CARCINOMA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENERAL CONDITION IMPROVEMENT; HERPES ZOSTER; HUMAN; HYPERSENSITIVITY; LEUKOENCEPHALOPATHY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; RECURRENT DISEASE; RELAPSING REMITTING MULTIPLE SCLEROSIS; SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS; SELF REPORT; SIDE EFFECT; SYNCOPE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 79955494219     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100011811     Document Type: Article

References (21)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology. 1993;43(4):655-61.
2. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, doubleblind, placebo-controlled trial. Neurology. 1995;45(7):1268-76.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3):285-94. (Pubitemid 26100751)
4. Ebers GC, Hommes O, Hughes RAC, et al. Randomised doubleblind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139): 1498-504. (Pubitemid 28512925)
5. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against 41 integrin. Nature. 1992; 356(6364):63-6.
6. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. Surface expression of ?4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med. 1993;177:57-68. (Pubitemid 23008085)
7. Lobb RR, Mehmler ME. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest. 1994;94(5):1722-8.
8. Polman CH, O-Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
9. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911-23.
10. Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007;62 (4):335-46. (Pubitemid 350105948)
11. Putzki N, Yaldizli O, Maurer M, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol. 2010;17(1):31-7.
12. Putzki N, Kollia K, Woods S, Egwe E, Diener HC, Limmroth V. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. Eur J Neurol. 2009;16 (3):424-6.
13. Oturai AB, Koch-Henriksen N, Petersen T, Jensen PEH, Sellebjerg F, Sorensen PS. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol. 2009;16:420-3.
14. Outteryck O, Ongagna JC, Zephir H, et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol. 2010;257:207-11.
15. Sangalli F, Moiola L, Bucello S, et al. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci. 2010. Epub 2010 June 11.
16. Belachew S, Phan-Ba R, Bartholome E, et al. Natalizumab induced a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol. 2010. Epub 2010 June 16.
17. Fernandez V, Alvarenga MP, Guerrero M, et al. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. Mult Scler. 2010. Epub 2010 Nov 18.
18. Bezabeth S, Flowers CM, Kortepeter C, Avigan M. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther. 2010;31(9):1028-35.
19. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BMJ, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008;70(13): 1150-1. (Pubitemid 351464749)
20. Miravalle A, Jensen R, Kinkel P. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2010. Epub 2010 Oct 11.
21. Borriello G, Prosperini L, Marinelli F, Fubelli F, Pozzilli C. Observations during an elective interruption of natalizumab treatment: a post-marketing study. Mult Scler. 2010. Epub 2010 Dec 9.